Skip to main content
    M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $144.52
    -3.24 (-2.19%)

    Market Cap: $364.26B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Merck & Company Inc (MRK) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Merck & Company (MRK) to earn $2.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $67.24B. Of 28 analysts, 19 rate the stock Buy or Strong Buy, 9 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 17 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 68% of the ratings.

    RatingAnalystsShare
    Strong Buy517.9%
    Buy1450.0%
    Hold932.1%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 223.0% and revenue estimates rise 3.3%.

    Fiscal year ending Dec 31, 2026
    $2.78
    EPS consensus, revenue $67.24B
    Fiscal year ending Dec 31, 2027
    $8.98
    EPS consensus, revenue $69.46B
    Next report
    Feb 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.78$2.50 to $2.9926$67.24B$66.84B to $67.75B25
    Dec 31, 2027$8.98$8.45 to $9.7525$69.46B$67.60B to $72.03B25

    Quarterly Estimates

    The EPS consensus rises from $1.76 for the quarter ending Dec 31, 2026 to $2.13 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.76$1.67 to $2.0119$16.45B$15.60B to $17.60B18
    Mar 31, 2027$2.13$1.97 to $2.279$16.45B$16.14B to $16.82B7

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 19 upward and 8 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026174
    Quarter ending Mar 31, 202724

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.5% from $2.74.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.78$2.77$2.69$2.75$2.74+1.4%
    Fiscal year ending Dec 31, 2027$8.98$9.02$9.32$9.55$9.55-5.9%
    Quarter ending Mar 31, 2027$2.13$2.13$2.16$2.21$2.21-3.5%

    Frequently Asked Questions About MRK

    What is the MRK stock forecast?

    Consensus analyst estimates put Merck & Company's EPS at $2.78 for the fiscal year ending Dec 31, 2026, on revenue of $67.24B. The consensus rating from 28 analysts is Buy.

    How do analysts rate MRK stock?

    Of 28 analysts covering Merck & Company, 5 rate it Strong Buy, 14 Buy, 9 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MRK next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.78, with estimates from $2.50 to $2.99 from 26 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.98, with estimates from $8.45 to $9.75 from 25 analysts.

    What revenue do analysts expect from Merck & Company next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $67.24B, with estimates from $66.84B to $67.75B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $69.46B, with estimates from $67.60B to $72.03B.

    How many analysts cover MRK?

    28 analysts rate Merck & Company stock, and 26 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.